Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB25FZX62
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,511
Award facts
- Contract value 100% obligated
- $2,510.63 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 mL vials. The contract, valued at $2,510.63 with a firm fixed-price structure, was executed on August 13, 2025, with an ultimate completion date of September 4, 2025. EXPAREL is a liposomal bupivacaine formulation used for extended local anesthesia, and this delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The award carries no set-aside designation.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently delivering specialized pharmaceutical products to Department of Defense healthcare facilities nationwide. The company's extensive portfolio of federal contract awards demonstrates its capability to supply everything from prescription medications and biologics to medical consumables across multiple therapeutic categories. This delivery order represents a routine procurement of a specialized pharmaceutical product to support military health facility operations, leveraging the company's established relationship with the DLA and its demonstrated expertise in pharmaceutical distribution to government healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FZX62?
SPE2DB25FZX62 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 13, 2025.
How much is contract SPE2DB25FZX62 worth?
The government has obligated $2,511 on SPE2DB25FZX62.
Is contract SPE2DB25FZX62 an order under another contract?
Yes. SPE2DB25FZX62 is a delivery order under SPE2DB20D9135, an indefinite delivery contract.
Was contract SPE2DB25FZX62 competed?
The extent of competition for SPE2DB25FZX62 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award